Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake.

doi:10.1152/ajpregu.00472.2011

Paper

Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake.

Published Dec 1, 2011 · N. Mckay, S. Kanoski, M. R. Hayes

American journal of physiology. Regulatory, integrative and comparative physiology

Q2 SJR score

55

Citations

1

Influential Citations

Full textSemantic Scholar

Abstract

Glucagon-like peptide-1 (GLP-1) is produced by and released from the small intestine following ingestion of nutrients. GLP-1 receptor (GLP-1R) agonists applied peripherally or centrally decrease food intake and increase glucose-stimulated insulin secretion. These effects make the GLP-1 system an attractive target for the treatment of type 2 diabetes mellitus and obesity. In addition to these more frequently studied effects of GLP-1R stimulation, previous reports indicate that GLP-1R agonists suppress water intake. The present experiments were designed to provide greater temporal resolution and site specificity for the effect of GLP-1 and the long-acting GLP-1R agonists, exendin-4 and liraglutide, on unstimulated water intake when food was and was not available. All three GLP-1R ligands suppressed water intake after peripheral intraperitoneal administration, both in the presence of and the absence of food; however, the magnitude and time frame of water intake suppression varied by drug. GLP-1 had an immediate, but transient, hypodipsic effect when administered peripherally, whereas the water intake suppression by IP exendin-4 and liraglutide was much more persistent. Additionally, intracerebroventricular administration of GLP-1R agonists suppressed water intake when food was absent, but the suppression of intake showed modest differences depending on whether the drug was administered to the lateral or fourth ventricle. To the best of our knowledge, this is the first demonstration of GLP-1 receptor agonists affecting unstimulated, overnight intake in the absence of food, the first test for antidipsogenic effects of hindbrain application of GLP-1 receptor agonists, and the first test of a central effect (forebrain or hindbrain) of liraglutide on water intake. Overall, these results show that GLP-1R agonists have a hypodipsic effect that is independent of GLP-1R-mediated effects on food intake, and this occurs, in part, through central nervous system GLP-1R activation.

Non-RCT

Study Snapshot

GLP-1 receptor agonists suppress water intake independently of their effects on food intake, potentially benefiting type 2 diabetes and obesity treatment.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake.

Sign up to use Study Snapshot

References

Comparative Effects of the Long‐Acting GLP‐1 Receptor Ligands, Liraglutide and Exendin‐4, on Food Intake and Body Weight Suppression in Rats

Liraglutide and exendin-4 both effectively suppress food intake and body weight in diet-induced obese rats, suggesting potential as clinical tools for obesity treatment.

Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.

Food intake suppression after peripheral administration of exendin-4 and liraglutide is mediated by both peripheral and central GLP-1R activation.

Ascending projections from the caudal visceral nucleus of the solitary tract to brain regions involved in food intake and energy expenditure

Ascending projections from the caudal visceral nucleus of the solitary tract to brain regions involved in food intake and energy expenditure modulate appetite, satiety, digestion, and metabolism.

Role of the glucagon-like-peptide-1 receptor in the control of energy balance

Pharmacological targeting of peripheral and central GLP-1 receptors may offer a potential long-term treatment option for obesity and type-II diabetes mellitus.

Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure.

GLP-1 infusion increased insulin levels and reduced glucose levels but had no major cardiovascular effects in patients without diabetes with compensated heart failure.

Citations

Targeting central pathway of Glucose-Dependent Insulinotropic Polypeptide, Glucagon and Glucagon-like Peptide-1 for metabolic regulation in obesity and type 2 diabetes.

Incretin-based anti-diabetic treatments, particularly glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonists, effectively regulate metabolic regulation in obesity and type 2 diabetes.

Glucagon-Like Peptide-1 Links Ingestion, Homeostasis, and the Heart.

GLP-1 plays a crucial role in regulating eating, insulin release, drinking control, kidney and cardiovascular functions, while maintaining essential nutrient intake.

Optimizing nutrition, diet, and lifestyle communication in GLP-1 medication therapy for weight management: A qualitative research study with registered dietitians

A comprehensive approach integrating patient communication, proactive side effect management, and ongoing lifestyle counseling is essential for optimizing GLP-1 medication therapy for obesity management.

Do relationships between ambient temperature and serious adverse health outcomes vary among users of different antidiabetes drugs? A retrospective cohort study of US Medicaid beneficiaries with type 2 diabetes

Ambient temperature has varying effects on serious glycemic outcomes in type 2 diabetes patients, with some drugs showing positive associations and others showing inverse associations.

Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events

Exenatide, liraglutide, and semaglutide are more susceptible to metabolic and nutritional adverse events, with dehydration being the most frequent serious outcome.

Nutritional considerations with antiobesity medications.

Antiobesity medications can lead to weight loss of 15%, but nutritional assessment, management, and monitoring are crucial for optimal health and well-being.